Marijo Bilusic - National Cancer Institute, National Institutes of Health

基本信息

Career Trajectory

Bio

Dr. Marijo Bilusic, MD, PhD, is a board certified medical oncologist who treats genitourinary tumors (adrenal, kidney, prostate, bladder, and testis). His current research interests focus on tumor immunology and development of novel immunotherapy approaches for prostate cancer and other genitourinary tumors using therapeutic cancer vaccines, antibodies, or immune modulators.

Research Interests

Papers共 155 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

TABLE 1 from Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells

Austin T.K. Hoke,Michelle R. Padget, Kellsye P. Fabian,Anjali Nandal,Gary L. Gallia,Marijo Bilusic, Patrick Soon-Shiong,James W. Hodge,Nyall R. London

crossref（2024）

Cited0Views0Bibtex

Supplementary Data from Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells

Austin T.K. Hoke,Michelle R. Padget,Kellsye P. Fabian,Anjali Nandal,Gary L. Gallia,Marijo Bilusic,Patrick Soon-Shiong,James W. Hodge,Nyall R. London

crossref（2024）

Cited0Views0Bibtex

FIGURE 5 from Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells

Austin T.K. Hoke,Michelle R. Padget,Kellsye P. Fabian,Anjali Nandal,Gary L. Gallia,Marijo Bilusic,Patrick Soon-Shiong,James W. Hodge,Nyall R. London

crossref（2024）

Cited0Views0Bibtex

FIGURE 4 from Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells

Austin T.K. Hoke,Michelle R. Padget,Kellsye P. Fabian,Anjali Nandal,Gary L. Gallia,Marijo Bilusic,Patrick Soon-Shiong,James W. Hodge,Nyall R. London

crossref（2024）

Cited0Views0Bibtex

FIGURE 7 from Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells

Austin T.K. Hoke,Michelle R. Padget,Kellsye P. Fabian,Anjali Nandal,Gary L. Gallia,Marijo Bilusic,Patrick Soon-Shiong,James W. Hodge,Nyall R. London

crossref（2024）

Cited0Views0Bibtex

FIGURE 6 from Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells

Austin T.K. Hoke,Michelle R. Padget,Kellsye P. Fabian,Anjali Nandal,Gary L. Gallia,Marijo Bilusic,Patrick Soon-Shiong,James W. Hodge,Nyall R. London

crossref（2024）

Cited0Views0Bibtex

A Phase II Multicenter Study of Enfortumab Vedotin with or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

Elias Chandran,Nicholas I. Simon,Daniel Da Motta Girardi,Lisa Ley,Tzu-Fang Wang,Andre Rashad Kydd,Saad Omar Atiq,Salah Boudjadi,Ian Stukes, Elizabeth Smith,Dilara Akbulut,Scot Anthony Niglio,Sandeep Gurram,Marijo Bilusic,Seth M. Steinberg,Andrea B. Apolo

Journal of Clinical Oncology（2024）

Cited0Views0Bibtex

FIGURE 3 from Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells

Austin T.K. Hoke,Michelle R. Padget,Kellsye P. Fabian,Anjali Nandal,Gary L. Gallia,Marijo Bilusic,Patrick Soon-Shiong,James W. Hodge,Nyall R. London

crossref（2024）

Cited0Views0Bibtex

FIGURE 2 from Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells

Austin T.K. Hoke,Michelle R. Padget, Kellsye P. Fabian,Anjali Nandal,Gary L. Gallia,Marijo Bilusic, Patrick Soon-Shiong,James W. Hodge,Nyall R. London

crossref（2024）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn